Senator Elizabeth Warren and Representative Lloyd Doggett are pushing for the U.S. Department of Commerce to finalize a proposal designed to address high drug costs by utilizing a mechanism known as “march-in” rights. This proposal would permit the government to take control of patents developed with taxpayer funding and lease them to generic drug manufacturers. The plan, according to Warren and Doggett, aims to ameliorate the financial burden of expensive medications on consumers by fostering competition and lowering prices.
Warren emphasized that this “popular framework” could be instrumental in reducing prescription drug costs, which remain a pressing issue for many Americans. For more detailed coverage on their legislative efforts, you can refer to the original article here.